cAMP signaling comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-07-02. Where a claim depends on a specific study, the study is described rather than over-claimed.
研究背景集中在特定人群的体成分改变，尤其是与脂肪分布异常相关的内脏脂肪堆积。不同地区对它的监管状态与获批适应症并不一致，部分市场仅限特定诊断人群使用。在一般人群中的长期效应、与其他激素的相互作用以及停药后的维持情况仍属开放问题，现有数据不足以给出普遍结论。
tesamorelin 是一种人工合成的四十四肽，序列与内源性生长激素释放激素（GHRH）的 1-44 片段一致，区别在于 N 端加接了一个反式-3-己烯酰基。该修饰抑制二肽基肽酶 IV 的快速切割，从而延长分子在循环中的存留时间。作为肽类分子，它难以经胃肠道吸收，文献中讨论的均是注射途径。分类上通常把它归为 GHRH 类似物，以区别于生长激素本身。
作用位置在垂体前叶。tesamorelin 与 GHRH 受体结合后激活腺苷酸环化酶，升高细胞内 cAMP，再经蛋白激酶 A 通路促进生长激素的合成与释放。由于它作用于内源调控节点，生长激素仍以脉冲方式分泌，而不是被持续抬升到固定水平。生长激素随后在肝脏等组织诱导胰岛素样生长因子 1 产生，构成完整的生长激素轴响应。
Pharmacodynamic studies show that tesamorelin reduces visceral adipose tissue more than subcutaneous adipose tissue in the studied population. This selectivity may relate to differences in blood flow and hormone sensitivity between fat depots. Effects on glucose metabolism and insulin sensitivity have been investigated, with some trials reporting modest changes and others showing stability. The precise relationship between growth hormone exposure, IGF-1 levels, and visceral fat loss remains an active area of analysis.
Tesamorelin binds to growth hormone-releasing hormone receptors on somatotroph cells in the anterior pituitary. Receptor activation increases intracellular cyclic AMP and promotes synthesis and secretion of growth hormone. Because the peptide mimics endogenous GHRH, it amplifies the normal pulsatile release of growth hormone rather than providing exogenous growth hormone directly. This upstream action distinguishes tesamorelin from recombinant growth hormone preparations and from growth hormone secretagogues that act at different receptors.
| 性质 | 取值 | 备注 |
|---|---|---|
| 分子类型 | 合成四十四肽 | GHRH 类似物 |
| N 端修饰 | 反式-3-己烯酰基 | 延缓酶切 |
| 分子量 | 约 5135 Da | 依序列与修饰 |
| 受体靶点 | 垂体 GHRH 受体 | 经 cAMP 通路 |
| 常见同义名 | GHRH(1-44) 类似物 | 文献通用称法 |
Tesamorelin binds to growth hormone-releasing hormone receptors on the surface of pituitary somatotroph cells. This binding activates adenylate cyclase, raising intracellular cyclic AMP levels and triggering the release of growth hormone into circulation. The elevated growth hormone then stimulates hepatic production of insulin-like growth factor 1. Because the effect is mediated through the endogenous axis, secretion remains subject to feedback regulation. This distinguishes it from direct growth hormone administration, which bypasses pituitary control entirely.
Clinical investigation has focused on HIV-associated lipodystrophy, a condition in which antiretroviral therapy contributes to abnormal fat distribution. Excess visceral adipose tissue accumulates in the abdomen while peripheral fat may be lost. Tesamorelin was evaluated for reducing this visceral fat depot, with trials measuring changes in abdominal fat by imaging rather than by body weight alone. The rationale rests on the known lipolytic effects of growth hormone. Effects on visceral fat are documented, while long-term outcomes regarding cardiovascular risk remain less clearly established.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone, composed of 44 amino acids. It was designed to retain the biological activity of the native hormone while resisting rapid enzymatic degradation. The compound is classified as a growth hormone secretagogue and belongs to the broader family of hypothalamic releasing factors. In research and clinical settings, it is studied for its ability to stimulate pituitary growth hormone release. Its structure includes a modification at the N-terminus that contributes to an extended half-life relative to native growth hormone-releasing hormone.
Tesamorelin binds the growth hormone–releasing hormone receptor on pituitary somatotroph cells. The receptor signals through the Gs protein, raising intracellular cAMP and activating protein kinase A. That cascade triggers release of stored growth hormone in pulses rather than a steady stream. Because the drug acts at the receptor that normally controls this process, its effect depends on the body's own signaling architecture rather than on a synthetic pathway. The resulting hormone profile reflects the timing of each pulse, not only its size.
Measured responses usually involve growth hormone and insulin-like growth factor 1, known as IGF-1. Growth hormone rises in bursts and is difficult to sample reliably, while IGF-1 shifts more slowly and can be assessed from a single blood draw. Studies therefore treat IGF-1 as the more practical pharmacodynamic marker. Both are indirect, showing that the receptor was engaged rather than that the peptide reached a particular concentration. Direct exposure measurement requires an assay aimed at the molecule itself.
232Th also very occasionally undergoes spontaneous fission rather than alpha decay, but at a much lower rate than uranium-238 and all natural fission products and evidence come predominantly from it. Its partial half-life for this process is very long at over 1021 years.
Hypotension (low blood pressure) Dysphoria Tachycardia Malaise Psychomotor impairment It is not believed to be addictive but is known to produce mild withdrawal effects (e.g., anorexia) after abrupt discontinuation.
By the time of the 2023 election, Peña was considered a conservative politician who opposes the legalization of abortion and same-sex marriage. In May 2017, however, he had stated that he was in favor of same-sex marriage, while saying in regards of abortion that he was open for it to "be discussed in a sincere environment and without prejudice". He reversed position shortly afterwards following criticism from conservative sectors. During his 2023 campaign, he promised to create 500,000 jobs. He also ruled out raising taxes. On foreign policy, Peña pledged to maintain Paraguay's diplomatic relations with the Republic of China (Taiwan). In May 2023, Peña announced that he intended to move the Paraguayan embassy in Israel from Tel Aviv to Jerusalem after being sworn in as president; a move that was previously made by Horacio Cartes in 2018, but reversed by Mario Abdo Benítez later that year. Peña eventually attended the inauguration of said embassy in December 2024. Peña and his government expressed vocal support for Israel during the Gaza war and the Twelve-Day War, with Paraguay siding with Israel during South Africa's genocide case against Israel. As president, Paraguay restored diplomatic relations with Venezuela in November 2023; relations were strained since 2019. Relations between the two nations were broken again in February 2025, however, after Peña recognized Edmundo González as the winner of the 2024 Venezuelan presidential election. On the 2026 United States intervention in Venezuela, Peña stated that "it can only bring good news".
Global Fossil Infrastructure Tracker API – the trade association of the US oil industry. (American Petroleum Institute) U.S. Energy Information Administration U.S. Department of Energy EIA – World supply and consumption Joint Organisations Data Initiative | Oil and Gas Data Transparency U.S. National Library of Medicine: Hazardous Substances Databank – Crude Oil "Petroleum" . The American Cyclopædia. 1879. "A Short History of Petroleum", Scientific American, August 10, 1878, p. 85
"Chains & Whips" contains a sample of "Take Five", composed by Paul Desmond, as performed by Cherry Wainer and Don Storer. "P.O.V." contains an interpolation of the Streets of San Francisco theme tune, composed by Patrick Williams. "So Be It" contains a sample of "Maza Akoolou", written by Fata El Shatea and Mohammed Abdel Wahab, and performed by Talal Maddah. "Inglorious Bastards" contains a sample of Jesse Jackson's opening speech to Wattstax. "Let God Sort Em Out / Chandeliers" contains a sample of the Sarge theme tune, composed by David Shire.
Sources: en.wikipedia.org
APEKTx1 is a highly selective blocker of the voltage-gated potassium channel Kv1.1 with no effect on other tested potassium channels (Kv1.2, Kv1.3, Kv1.4, Kv1.5, Kv1.6, Shaker IR, Kv2.1, Kv3.1, Kv4.2 and Kv4.3). APEKTx1 selectively blocks Kv1.1 channels with an IC50 value of 0.9 nM, which makes it between a 700 to 3000 times more potent inhibitor than the two known sea anemone peptides targeted against Kv channels (kalicludines and SHTX II). APEKTx1 is thought to interact with Kv1.1 through the aliphatic residue alanine (A352), an acidic residue glutamate (E353), and an aromatic residue tyrosine (Y379), as a mutation in these sites causes a loss in affinity of the toxin for Kv1.1. These residues are located in the H5-loop between the S5 and S6 domains and are part of the channel’s pore. In addition, APEKTx1 acts as a potent trypsin inhibitor (Kd= 124 nM), probably a competitive one. However, trypsin inhibition is more potent (as it has a higher affinity) in BPTI, which can be explained by the presence of Phe13 and Pro19 in APEKTx1, causing an unfavorable interaction.
Profilin was first described by Lars Carlsson in the lab of Uno Lindberg and co-workers in the early 1970s as the first actin monomer binding protein. It followed the realization that not only muscle, but also non-muscle cells, contained high concentrations of actin, albeit in part in an unpolymerized form. Profilin was then believed to sequester actin monomers (keep them in a pro-filamentous form), and release them upon a signal to make them accessible for fast actin polymer growth.
Technetium is a chemical element; it has symbol Tc and atomic number 43. It is the lightest element whose isotopes are all radioactive. Technetium is one of only two radioactive elements both preceded and succeeded in the periodic table by elements with stable forms, the other being promethium. All available technetium is produced as a synthetic element. Naturally occurring technetium is a spontaneous fission product in uranium ore and thorium ore (the most common source), or the product of neutron capture in molybdenum ores. This silvery gray, crystalline transition metal lies between manganese and rhenium in group 7 of the periodic table, and its chemical properties are intermediate between the two. The most common naturally occurring isotope is 99Tc, in traces only. Many of technetium's properties had been predicted by Dmitri Mendeleev before it was discovered; Mendeleev noted a gap in his periodic table and gave the undiscovered element the provisional name ekamanganese (Em). In 1937, technetium became the first predominantly artificial element to be produced, hence its name (from the Greek technetos, 'artificial', + -ium). One short-lived gamma-ray–emitting nuclear isomer, technetium-99m, is used in nuclear medicine for a wide variety of tests, such as bone cancer diagnoses. The ground state of the nuclide technetium-99 is used as a gamma-ray–free source of beta particles. Long-lived technetium isotopes produced commercially are byproducts of the fission of uranium-235 in nuclear reactors and are extracted from nuclear fuel rods.
=== Type 1 diabetes === Insulin degludec was studied as an alternative to insulin glargine as part of a basal-bolus regimen in the BEGIN Basal-Bolus Type 1 trial. 629 participants with type 1 diabetes were randomized in a 3:1 ratio to either insulin degludec (n=472) or insulin glargine (n=157) in addition to mealtime insulin aspart. Participants in the degludec treatment arm were switched from their basal insulin to insulin degludec in a 1:1 ratio, with a 20-30% dose reduction in participants receiving multiple basal doses per day. After 52 weeks, participants treated with insulin degludec produced a similar reduction in HbA1c (0.40% vs. 0.39%) meeting the criteria for noninferiority. Adverse events were similar in the two treatment arms; however, rates of nocturnal hypoglycemia (between midnight and 6am) were 27% lower in participants treated with insulin degludec (3.91 vs. 5.22 episodes per patient-year of exposure, p=0.024). The reduction in the incidence of hypoglycemia was seen as a therapeutic benefit, as hypoglycemia is often a dose limiting toxicity in insulin therapy. A systematic review has compared the use of insulin degludec to that of insulin glargine, insulin detemir and NPH insulin in adults and children diagnosed with type 1 diabetes. This review included Randomized Control Trials (RCTs) with a duration of 24 to 104 weeks and had a total sample of 8784 participants randomized across studies: 2428 participants allocated to NPH insulin; 2889 participants to insulin detemir; 2095 participants to insulin glargine; 1372 participants to insulin degludec.
Sources: en.wikipedia.org
tesamorelin 属 GHRH 类似物，作用于垂体受体以促进内源生长激素释放；生长激素本身是直接补充的外源激素。两者在给药逻辑、作用位点和反馈调控路径上并不相同。
作为多肽，它难以通过胃肠道吸收，通常需要注射给药。口服会因消化酶降解而失去活性，因此文献中讨论的都是注射途径。
公开研究多集中在内脏脂肪、体成分分布以及与生长激素轴相关的代谢指标。长期安全性和在普通人群中的适用性尚缺乏一致结论。
It targets the growth hormone-releasing hormone receptor on pituitary somatotroph cells. Binding stimulates cyclic AMP signaling and growth hormone secretion. This is the same receptor used by endogenous GHRH.